Skip to content

Ionis Pharmaceuticals

US · IONS #1749 by market cap Listed 1970
26.58 -0.64 -2.35%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:59

Valuation each multiple against its own 5-year range

P/B ratio 12.29 In line with history 48th percentile
5-year average 14.86 · #469 of 514 in Biotechnology
P/E ratio -8.67 Expensive vs history 89th percentile
5-year average -104.26 · forward -8.00
P/S ratio 5.04 Cheap vs history 0th percentile
5-year average 8.84 · forward 4.93 · #119 of 389 in Biotechnology

Vs. peers Biotechnology

Company Market cap P/E (TTM) P/B Div yield
Ionis Pharmaceuticals (IONS) 4.43B -7.93 11.24 0.00%
Vertex Pharmaceuticals (VRTX) 130.58B 33.14 6.25 0.00%
Regeneron Pharmaceuticals (REGN) 95.24B 20.35 2.84 0.40%
Moderna (MRNA) 78.90B -27.70 11.54 0.00%
argenx SE (ARGX) 58.21B 32.06 6.92 0.00%
BeiGene (ONC) 44.66B 49.74 7.67 0.00%

Other StockVane-tracked companies in the same industry.

Morningstar

★★★★★ Fair value80.00 Economic moatNarrow UncertaintyHigh Capital allocationStandard

Trading 201.0% below Morningstar's fair value estimate.

Analyst note

Ionis reported third-quarter revenue of $243 million, up 55% year over year. While management reaffirmed 2026 revenue, operating loss, and cash guidance, it cut 2026 Tryngolza (for sHTG/FCS) revenue guidance by 50% to approximately $50 million, triggering a 21% decline in the shares on Nov. 9.

Why it matters: The market's reaction reflects the much slower-than-expected rollout for Tryngolza since its June 2026 approval in sHTG, which significantly expands its patient population beyond the very rare indication of FCS. As the first RNA-targeting therapy approved to reduce triglycerides and pancreatitis risk, Tryngolza faces the challenges of market creation, physician education, and payer coverage. We believe investors are overlooking Ionis' increasingly diverse revenue base. Beyond Tryngolza, the company has two wholly owned launches, growing royalty streams, and multiple late-stage partnered assets. Dawnzera (for HAE) generated $37 million in quarterly sales and grew more than 40% sequentially, emerging as a meaningful commercial growth driver.

The bottom line: We lowered narrow-moat Ionis' fair value estimate to $80 per share from $84, reflecting a slower near-term commercial ramp of Tryngolza. Shares are trading at a steep discount in 5-star territory. We believe the launch bottleneck is operational rather than demand-driven, given its strong clinical profile. Despite incorporating Arrowhead's Redemplo, pricing pressure, and selective use among the highest risk sHTG patients, we forecast nearly $2 billion in combined US sales and ex-US royalties by 2035. Although management pushed out its timeline for positive cash flow from 2028 to 2029, we view this as a timing issue rather than a structural concern. With a substantial cash balance of $1.9 billion and multiple commercial and pipeline catalysts, Ionis has flexibility to navigate near-term launch challenges.

Fair value

We lowered narrow-moat Ionis' fair value estimate to $80 per share from $84, reflecting a slower near-term commercial ramp of Tryngolza. As the first RNA-targeting therapy approved to reduce triglycerides and pancreatitis risk, Tryngolza faces the challenges of market creation, physician education, and payer coverage. We believe the launch bottleneck is operational rather than demand-related, given its strong clinical profile.

In December 2024, Ionis received US approval for Tryngolza as the first treatment approved for adults with familial chylomicronemia syndrome, a rare genetic disorder that leads to dangerously high triglyceride levels. Tryngolza’s annual list price was $595,000 for this very rare condition affecting about 3,000 patients in the US.

In September 2025, Ionis reported top-line data from the phase 3 study of olezarsen in severe hypertriglyceridemia. Compared with a placebo, olezarsen lowered triglycerides by up to 72%, and it led to an impressive 85% reduction in acute pancreatitis events. In June 2026, the FDA approved Tryngolza in sHTG, which expands its label to an estimated 3 million patients.

Ionis proactively positioned Tryngolza for the broader sHTG opportunity by reducing the annual list price to $40,000 from $595,000, which should improve patient access and support volume growth. We believe the launch bottleneck is operational rather than demand-driven, given its strong clinical profile. Despite incorporating Arrowhead's Redemplo, pricing pressure, and selective use among the highest-risk sHTG patients, we forecast nearly $2 billion in combined US sales and ex-US royalties by 2035.

Ionis relies on upfront payments and licensing fees from partners, as well as Spinraza royalties, to drive revenue today, but its rapidly advancing portfolio should help diversify revenue. We believe investors are overlooking Ionis' increasingly diverse revenue base. Beyond Tryngolza, the company has two wholly owned launches, growing royalty streams, and multiple late-stage partnered assets. Dawnzera (for HAE) generated $37 million in third-quarter sales and grew more than 40% sequentially, emerging as a meaningful commercial growth driver.

Ionis received US approval in 2025 for Dawnzera, marking the first and only RNA-targeted prophylactic treatment for hereditary angioedema. HAE is a rare genetic condition that causes sudden and potentially life-threatening swelling in various parts of the body. There are about 20,000 people with this condition in the US and EU. Management has guided to annual peak sales potential for Dawnzera in excess of $500 million, but we think with the January 2026 approval in the EU, this drug could achieve total sales of $775 million by the end of our 10-year forecast.

We remain positive on Ionis' risk/reward profile given its expanding commercial portfolio, healthy balance sheet with $1.9 billion in cash and short-term investments at the end of the third quarter of 2026, and multiple late-stage catalysts that could support meaningful value creation over the next several years. We maintain our positive long-term outlook and project a five-year compound annual revenue growth rate of over 25%.

We assign the firm an 8.6% weighted average cost of capital, heavily driven by our assumption of a 9.1% cost of equity. This cost of equity is consistent with other emerging biotech companies in our coverage and what we view as the systematic risk associated with its shares.

Economic moat

Ionis has proprietary antisense oligonucleotide technology that has led to several approved RNA-based drugs and a steadily growing pipeline, which together support the firm’s intangible assets and Morningstar Economic Moat Rating of narrow. Ionis has attracted large partners such as Biogen and Roche, and it has one of the most diverse pipelines in the biotech sector. Even if some of its drugs fail to reach the market, Ionis has reduced development risks by partnering on programs that require large clinical trials. The company continues to replenish its pipeline and improve the safety and convenience of its targeted ASO therapy, and we expect it to gain approval for several additional drugs over the next couple of years, driving excess returns during our forecast period.

Similar to other biotechnology and pharmaceutical firms under our coverage, we think Ionis faces environmental, social, and governmental risks related to US drug price policy reform and the ongoing potential for product governance issues, including litigation. While we have factored these threats into our analysis, we don’t see them as material to our valuation or moat rating for Ionis.

Ionis holds a dominant intellectual property position in the field of antisense oligonucleotides, using human genetics data and the effects of known genetic variations to validate new programs. Most of Ionis’ ASOs prevent RNA from being translated into a protein that drives disease, although approved spinal muscular atrophy drug Spinraza modulates splicing to increase protein levels. Even as patents on older forms of technology expire, Ionis maintains layers of intellectual property protection, with patents on individual therapies and next-generation technologies (typically allowing smaller doses or more convenient administration) to renew this protection over time. For example, patents on the firm's generation 2.0 technology expired in 2023, but generation 2.5 and LICA—ligand conjugated antisense—delivery technology have extended protection through 2027 and 2034, respectively.

Ionis also has lengthy patent protections on individual drugs, including Spinraza (patent until 2030), Wainua (through at least 2034), Tryngolza (approved by the FDA in December 2024), and Dawnzera (approved by the FDA in August 2025). We think Ionis' Dawnzera has a best-in-class profile in hereditary angioedema, a rare, potentially life-threatening condition that causes severe recurring swelling in the body. We think this drug could achieve total sales exceeding $700 million by the end of our 10-year forecast period.

Ionis’ portfolio is a mix of partnerships and wholly owned projects. Outsourcing its higher-cost clinical trials to larger pharmaceutical firms helps avoid major value destruction, even if several programs fail to reach the market. Ionis typically partners on larger opportunities after completing smaller proof-of-concept studies and maintains full rights to treatments for diseases that are rare or have midsize patient populations. Research and development expenses kept Ionis in the red before 2018, and while Ionis turned a profit in 2019-20 due to significant collaboration revenue from new, expanded, and advancing partnerships, we expect continued operating losses through 2028.

The pipeline has several therapies using the firm's liver-targeting LICA technology, which allows lower dosages and reduced side effects while improving potency and convenience. For example, Ionis’ older-technology drug Tegsedi was approved in 2018 as a once-weekly injection for polyneuropathy in hereditary ATTR amyloidosis, but with a black box warning on its prescribing label for thrombocytopenia (low platelet count) and glomerulonephritis (kidney disease). Alnylam's infused drug Onpattro, approved two months earlier, has a better safety profile and has seen better commercial success. In addition, Pfizer's oral Vyndaqel/Vyndamax has been approved for another amyloidosis indication, cardiomyopathy, which does overlap with polyneuropathy and could pull some patients onto this convenient and cheaper regimen. Ionis' next-generation LICA drug Wainua (for amyloidosis) has demonstrated improved potential over Tegsedi. It received approval in the US in December 2023 and received a positive opinion by the Committee for Medicinal Products for Human Use in the European Union in October 2024. Additionally, Tryngolza (for severe hypertriglyceridemia) has demonstrated improved potential over Ionis’ older drug Waylivra. It received FDA approval in December 2024, marking Ionis’ first independent commercial launch as it historically depended on larger pharmaceutical firms for commercialization efforts. Ionis will be focused on Tryngolza’s commercialization efforts in the US market.

In neurology, RNA therapies can reach their intended targets via intrathecal administration into spinal fluid, directly preventing the production of toxic proteins. The approval of Spinraza in 2016 and Qalsody in 2023 provided a solid foundation for Ionis' neurology pipeline. Partner Biogen's reported Spinraza revenue of roughly $2 billion annually in 2019-21 declined to $1.55 billion in 2025 as Biogen added new patients at lower price points and sees some share loss to newer treatments like one-time gene therapy Zolgensma (Novartis) and oral small-molecule treatment Evrysdi (Roche). However, share loss could be mitigated thanks to Ionis’ progress with a higher-dose version of Spinraza and next-generation drugs that could see dosing every nine months or yearly, instead of every four months.

Ionis is retaining full rights to several programs in neurology, including pivotal programs for Angelman syndrome and Alexander disease. As Ionis’ pipeline continues to develop, we think it is likely that the firm will see returns above our assumed 8.6% cost of capital by 2030.

Bull case

Ionis' antisense technology and intellectual property estate have allowed the firm to create an entirely new class of therapeutics for difficult-to-treat diseases.

Antisense therapeutics have the potential to gain access to well-studied targets in the cell that are currently deemed “undruggable,” and Ionis could capture this low-hanging fruit in a wide range of diseases.

Ionis has attracted big-name partners like Biogen and Roche, and it has one of the broadest pipelines in the biotech sector.

Bear case

Beyond recent strong collaboration revenue, Ionis has historically been unprofitable, and RNA-based therapies have had a long path to market.

While Ionis targets several rare genetic disorders, including amyloidosis and spinal muscular atrophy, the space is attracting greater biopharma competition.

Ionis partnering with large pharma firms limits the economic profits the company can derive from a successful drug.

By Rachel Elfman

Quote time 2026-11-20 19:59:29 · For reference only, not investment advice and not tailored to your situation.

Ionis Pharmaceuticals discussion 0 comments

Add a comment